Vireo Health Targets FDA-Approved Cannabis Treatment for Chronic Pain

Vireo Grower
Vireo Health of New York Chief Cultivator Chuck Schmitt (John Carl D’Annibale / Times Union)

The Albany Times Union has reported that Vireo Health of New York, formerly Empire State Health Solutions, will use the Captisol technology that it has licensed from Ligand Pharmaceuticals to pursue a pharmaceutical grade medical cannabis solution to a large and poorly treated medical condition:

The initial focus will be to develop cannabinoid medications for treatment of chronic pain, at a time when abuse of opioid painkillers is soaring, according to Vireo Chief Medical Officer Laura Bultman.

Vireo Health announced the licensing of Ligand’s technology on Wednesday.

Read Claire Hughes’ “Parent of N.Y. medical marijuana company seeks to make FDA-approved drugs”: http://blog.timesunion.com/healthcare/parent-of-n-y-medical-marijuana-company-seeks-to-make-fda-approved-drugs/4027/

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter